Detalhe da pesquisa
1.
Cooperative CAR targeting to selectively eliminate AML and minimize escape.
Cancer Cell
; 41(11): 1871-1891.e6, 2023 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37802054
2.
Integrated multiomic approach for identification of novel immunotherapeutic targets in AML.
Biomark Res
; 10(1): 43, 2022 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35681175
3.
HLA-independent T cell receptors for targeting tumors with low antigen density.
Nat Med
; 28(2): 345-352, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35027758
4.
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia.
Mol Cancer Ther
; 19(9): 1875-1888, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32518207
5.
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
J Exp Med
; 216(5): 1170-1181, 2019 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30910796
6.
Recent developments in immunotherapy of acute myeloid leukemia.
J Hematol Oncol
; 10(1): 142, 2017 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743264
7.
Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.
Oncoimmunology
; 5(9): e1175794, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27757295
8.
Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.
Cancer Res
; 75(21): 4483-93, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26432403